Skip navigation

Industry Best Practices and Strategies for Managing and Enhancing Ethics and Integrity Programs

June 6-7, 2017
  • Toronto, Canada

CBI Presents the First Ever Canadian Compliance Congress —
For Canada, in Canada!

With increasing efforts to strengthen company-wide ethics and integrity, as well as new efforts to establish transparency reporting, it is more important than ever to strengthen compliance programs. CBI’s Pharmaceutical Compliance Congress Canada brings together industry experts to share best practices and insights on key issues facing Canadian compliance teams, including constructing training and monitoring programs to bolster an organizational culture of integrity, applying Canadian anti-corruption legislation, and ensuring promotional materials meet Health Canada regulations.

A Dialogue-Driven Forum to Address Ethics and Integrity Issues in Canada:

  • Identify the core concepts required to build a culture of compliance and the pivotal role that ethics play
  • Determine the distinction between promotional and non-promotional activities and address the inherent risks
  • Achieve organization-wide compliance, from the compliance and legal teams to the promotional marketing and sales teams
  • Respond to the changing landscape of continuing medical education
  • Resolve potential privacy concerns where social media and patient medical information intersect
  • Implement innovative strategies to enhance compliance training and monitoring
  • Mitigate risk and optimize third-party relationships
Hear Perspectives from Top Canadian Compliance Practitioners and Leading Experts Representing:

GSK Canada Diabetes Canada Ryerson University AstraZeneca Canada
Johnson & Johnson Medical Devices Janssen Canada Teva Pharmaceuticals
Innovative Medicines Canada Astellas Pharma Canada AbbVie Integrated
Pharma Services Gilead Sciences Canada Pharmaceutical Advertising
Advisory Board Norton Rose Fulbright Canada Purdue Pharma Canada
Polaris Bayer Otsuka Canada Pharmaceuticals
Royal College of Physicians and Surgeons of Canada and more

A SPECIAL THANK YOU TO OUR
DISTINGUISHED ADVISORY BOARD MEMBERS

Annie Bourgault,
Ethics & Compliance Officer, Canada Pharma, GlaxoSmithKline Inc.

Tina Gaglietta,
Ethics and Compliance Lead, Canada, AbbVie Corp.

Chrisoula Nikidis,
Vice-President, Ethics, Integrity and Governance, Innovative Medicines Canada

Rosy Sasso,
Ethics, Compliance & Privacy Consultant, Rosy Sasso Inc.

Crawford Wright,
Chief Compliance and Privacy Officer, AstraZeneca Canada

June 6-7, 2017 | Radisson Admiral Hotel | Toronto, Canada

Pharmaceutical Compliance Congress Canada

Industry Best Practices and Strategies for Managing and Enhancing Ethics and Integrity Programs

CBI Presents the First Ever Canadian Compliance Congress —
For Canada, in Canada!

With increasing efforts to strengthen company-wide ethics and integrity, as well as new efforts to establish transparency reporting, it is more important than ever to strengthen compliance programs. CBI’s Pharmaceutical Compliance Congress Canada brings together industry experts to share best practices and insights on key issues facing Canadian compliance teams, including constructing training and monitoring programs to bolster an organizational culture of integrity, applying Canadian anti-corruption legislation, and ensuring promotional materials meet Health Canada regulations.

A Dialogue-Driven Forum to Address Ethics and Integrity Issues in Canada:

  • Identify the core concepts required to build a culture of compliance and the pivotal role that ethics play
  • Determine the distinction between promotional and non-promotional activities and address the inherent risks
  • Achieve organization-wide compliance, from the compliance and legal teams to the promotional marketing and sales teams
  • Respond to the changing landscape of continuing medical education
  • Resolve potential privacy concerns where social media and patient medical information intersect
  • Implement innovative strategies to enhance compliance training and monitoring
  • Mitigate risk and optimize third-party relationships
Hear Perspectives from Top Canadian Compliance Practitioners and Leading Experts Representing:

GSK Canada Diabetes Canada Ryerson University AstraZeneca Canada
Johnson & Johnson Medical Devices Janssen Canada Teva Pharmaceuticals
Innovative Medicines Canada Astellas Pharma Canada AbbVie Integrated
Pharma Services Gilead Sciences Canada Pharmaceutical Advertising
Advisory Board Norton Rose Fulbright Canada Purdue Pharma Canada
Polaris Bayer Otsuka Canada Pharmaceuticals
Royal College of Physicians and Surgeons of Canada and more

A SPECIAL THANK YOU TO OUR
DISTINGUISHED ADVISORY BOARD MEMBERS

Annie Bourgault,
Ethics & Compliance Officer, Canada Pharma, GlaxoSmithKline Inc.

Tina Gaglietta,
Ethics and Compliance Lead, Canada, AbbVie Corp.

Chrisoula Nikidis,
Vice-President, Ethics, Integrity and Governance, Innovative Medicines Canada

Rosy Sasso,
Ethics, Compliance & Privacy Consultant, Rosy Sasso Inc.

Crawford Wright,
Chief Compliance and Privacy Officer, AstraZeneca Canada

June 6-7, 2017 | Radisson Admiral Hotel | Toronto, Canada